Innate Pharma announces its financial calendar for 2019

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
19
Innate Pharma announces its financial calendar for 2019

INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2019    

Marseille, France, January 10, 2019, 7:00 AM CET

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2019, which is set as follows:

March 20, 2019:         Publication of 2018 financial statements, with management comments. The 2018 Reference Document and Financial Report (included in the Reference Document) will be released during the second quarter of 2019.

May 15, 2019:            Publication of revenue for 1Q2019, with management comments.

May 22, 2019:            Annual shareholders meeting in Marseille.

September 13, 2019:   Publication of financial statements as of June 30, 2019, with management comments.

November 13, 2019:    Publication of revenue for 3Q2019, with management comments.

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section ( http://www.innate-pharma.com/en/investors/ )

About Innate Pharma:

Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca/MedImmune. 

Based in Marseille, France, Innate Pharma is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code Ticker code LEI FR0010331421 IPH 9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website www.amf-france.org or on Innate Pharma’s website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors   Innate Pharma  Dr. Markus Metzger / Danielle Spangler / Jérôme Marino Tel.: +33 (0)4 30 30 30 30 investors@innate-pharma.com   International Media   Consilium Strategic Communications Mary-Jane Elliott / Jessica Hodgson Tel.: +44 (0)20 3709 5700 InnatePharma@consilium-comms.com
  French Media   ATCG Press Marie Puvieux Mob: +33 (0)6 10 54 36 72 presse@atcg-partners.com  

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 19

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 21

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 74

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 50

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 31

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 49

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 101

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 217

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating Component Obsolescence: Key Trends and Insights

Updated Category News Views 170

Understanding Component Obsolescence in Today's Market In the rapidly evolving world of semiconductors and electronic components, tracking obsolescence has become crucial. Bill Bradford, President of Flip Electronics, sheds light on these trends that are shaping the industry as we move towards 2026. The market has seen a significant shift, primarily due to increasing...

Continue Reading
Exploring Class Action Claims Against iLearningEngines - AILE

Updated Category News Views 181

Understanding the Class Action Lawsuit Against iLearningEngines Faruqi & Faruqi, LLP, a prominent name in securities litigation, is taking steps to inform investors about a significant class action lawsuit related to iLearningEngines, Inc. The law firm, known for its commitment to protecting investors' rights, has set a deadline for potential lead plaintiffs in this case....

Continue Reading
Key Stock Movements: Sanmina and other Performers Soar

Updated Category News Views 440

Key Stock Movements on Tuesday U.S. stocks exhibited mixed performance with the Dow Jones index declining around 100 points. Despite the overall market volatility, several companies reported substantial improvements in their stock values on Tuesday. Sanmina Corporation Performance Sanmina Corporation (NASDAQ: SANM) saw an impressive rise in its stock during Tuesday's...

Continue Reading
Segal Trials' Innovations in Schizophrenia Treatment with LB-102

Updated Category News Views 303

Segal Trials Advances Schizophrenia Research with LB-102 Segal Trials is making significant strides in the field of schizophrenia research, focusing on the innovative treatment method involving LB-102. This investigational drug, which is a potential first-in-class benzamide antipsychotic, is being evaluated in a Phase 2 trial. The main goal of this study is to assess the...

Continue Reading
Innovative Vehicle Safety System Promises Improved Driver Focus

Updated Category News Views 237

Introduction to an Innovative Safety Solution In today's fast-paced world, driving distractions can have serious consequences. An inventive mind has created a new device called SAFE DRIVE, aimed at enhancing driver concentration and reducing the risks associated with smartphone usage while driving. Concept Behind SAFE DRIVE The SAFE DRIVE invention is designed with a...

Continue Reading